ERBB2 and breast carcinoma: An in vitro study exploring the effects of the SCFA butyrate on HER2 overexpressing SKBR3 breast cancer cell line found that anticancer effects of butyrate were significantly enhanced in combination with trastuzumab via increased p27Kip1 (147).